OTCMKTS:PMCUF - Pro Medicus Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$33.51
▼ -0.331 (-0.98%)
1 month | 3 months | 12 months
Get New Pro Medicus Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PMCUF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PMCUF

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Pro Medicus in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $33.51.
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Pro Medicus. This rating has held steady since June 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
2/17/2021The Goldman Sachs GroupUpgradeNeutral ➝ Buy
i
1/13/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
i
8/21/2020UBS GroupUpgradeNeutral ➝ Buy
i
6/25/2019Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform
i
5/29/2019The Goldman Sachs GroupInitiated CoverageNeutral
i
(Data available from 3/7/2016 forward)
Pro Medicus logo
Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions in Australia, Europe, and North America. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.
Read More

Today's Range

Now: $33.51
$33.51
$33.51

50 Day Range

MA: $33.32
$24.39
$37.48

52 Week Range

Now: $33.51
$8.30
$37.48

Volume

105 shs

Average Volume

1,615 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Pro Medicus?

The following sell-side analysts have issued stock ratings on Pro Medicus in the last year: Royal Bank of Canada, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for PMCUF.

What is the current price target for Pro Medicus?

0 Wall Street analysts have set twelve-month price targets for Pro Medicus in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Pro Medicus in the next year.
View the latest price targets for PMCUF.

What is the current consensus analyst rating for Pro Medicus?

Pro Medicus currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PMCUF will outperform the market and that investors should add to their positions of Pro Medicus.
View the latest ratings for PMCUF.

What other companies compete with Pro Medicus?

How do I contact Pro Medicus' investor relations team?

The company's listed phone number is 61 3 9429 8800. The official website for Pro Medicus is www.promed.com.au.